Drugs / GR2001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06302374 | Mar → Nov 2023 | tetanus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06635798 | Sep → Dec 2024 overdue | tetanus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06635798 ↗ |
| Route | Intramuscular | “single IM gluteal injection of GR2001” NCT06635798 ↗ |